MSN Pharmaceuticals Wins Patent Dispute Against Novartis Over Heart Failure Drug Entresto

In a recent legal development, MSN Pharmaceuticals Inc. emerged victorious against Novartis in a patent infringement case centered on the heart failure drug, Entresto. The decision, rendered by a Delaware federal judge, concluded that Novartis was unable to substantiate its claims that MSN had violated patent rights associated with the branded medication. This outcome represents a significant instance in Novartis’ continuing efforts to prevent the introduction of a generic counterpart to their lucrative drug. For a more detailed exploration of the case, legal professionals may refer to the comprehensive coverage provided by Law360.